Doxorubicin-loaded polysaccharide nanoparticles suppress the growth of murine colorectal carcinoma and inhibit the metastasis of murine mammary carcinoma in rodent models

Biomaterials
Mingqiang LiXuesi Chen

Abstract

As a synergistic drug combination, doxorubicin-loaded cisplatin crosslinked polysaccharide-based nanoparticles (Dex-SA-DOX-CDDP) have demonstrated enhanced antitumor efficacy and reduced systemic toxicity via optimized biodistribution, controlled drug release, prolonged blood circulation, and improved tolerability, compared to the non-crosslinked nanoparticles or free doxorubicin. Herein, we apply the Dex-SA-DOX-CDDP nanoparticles as an efficient antitumor agent to treat colorectal and breast tumors in three different in vivo models, i.e. subcutaneously implanted colorectal carcinoma, dimethylhydrazine-induced autochthonous colorectal carcinoma, and metastatic mammary carcinoma, which more closely simulate the natural milieu of the original tumor with intact pathological and immunological responses. Based on the properties of this combination in higher tumor accumulation and penetrating efficiency, the Dex-SA-DOX-CDDP nanoparticles significantly decreased the tumor sizes in CT26 cell line xenograft tumors compared to control. In addition, the affected animals' lifespan was significantly extended after the Dex-SA-DOX-CDDP treatment, in the autochthonous colon cancer model. Moreover, with the aid of iRGD, Dex-SA-DOX-CDDP could ef...Continue Reading

References

Jan 1, 1986·Journal of Cancer Research and Clinical Oncology·H Amberger
Jan 10, 2004·Clinical & Experimental Metastasis·Darlene E JenkinsPamela R Contag
Apr 6, 2006·Cancer Research·Oren J Becher, Eric C Holland
Aug 18, 2006·Nature Reviews. Drug Discovery·Norman E Sharpless, Ronald A Depinho
Apr 5, 2007·Nature Protocols·Christopher L Morton, Peter J Houghton
Feb 12, 2008·Journal of Controlled Release : Official Journal of the Controlled Release Society·Srinivas GantaMansoor Amiji
Jul 26, 2008·Nature Nanotechnology·Dan PeerRobert Langer
Aug 29, 2009·Nature Protocols·Erika L AbelJohn DiGiovanni
Oct 7, 2009·Proceedings of the National Academy of Sciences of the United States of America·Tambet TeesaluErkki Ruoslahti
Mar 6, 2010·Journal of the American Chemical Society·Kheireddine El-BoubbouXuefei Huang
Mar 26, 2011·Science·Christine L Chaffer, Robert A Weinberg
Jul 18, 2012·Journal of Controlled Release : Official Journal of the Controlled Release Society·Sebastien TaurinKhaled Greish
Sep 26, 2012·ACS Nano·Pubudu M PeirisEfstathios Karathanasis
Feb 7, 2013·Journal of Cellular Biochemistry·Giuseppe RoscilliGennaro Ciliberto
Jun 7, 2013·Advanced Materials·Jinqiang WangZhongwei Gu
Jun 8, 2013·Journal of Controlled Release : Official Journal of the Controlled Release Society·Jianxun DingXuesi Chen
Jul 16, 2013·Advanced Healthcare Materials·Chun-Yang SunJun Wang
Dec 20, 2013·Science Translational Medicine·Edward Kai-Hua Chow, Dean Ho

❮ Previous
Next ❯

Citations

Apr 5, 2016·Advanced Drug Delivery Reviews·Erkki Ruoslahti
Aug 4, 2015·Molecular Pharmaceutics·Qianyu ZhangQin He
Jul 13, 2016·Expert Opinion on Drug Delivery·Qingxin MuMiqin Zhang
Oct 18, 2016·Medicina·Raimonda KubiliūtėSonata Jarmalaitė
Jul 15, 2017·Biomacromolecules·Richard SleightholmDavid Oupický
Jul 3, 2018·Journal of Pharmaceutical Investigation·Debadyuti GhoshRashmi Mohanty
Mar 31, 2017·Molecular Medicine Reports·Hong YinJunnian Zheng
Oct 31, 2019·Journal of Oncology·Riccardo RampadoMarco Agostini
Jul 7, 2017·Journal of Materials Chemistry. B, Materials for Biology and Medicine·Yuqian GaoShaobing Zhou
Sep 25, 2019·Materials Science & Engineering. C, Materials for Biological Applications·Sushma HavanurNitesh Kumar
Jan 14, 2020·European Journal of Medicinal Chemistry·Zahra ShabaninejadHamed Mirzaei
May 22, 2018·ACS Applied Materials & Interfaces·Yazhou ChenJing Huang
Jan 10, 2017·Biomacromolecules·Nilesh Umakant Deshpande, Manickam Jayakannan
Oct 14, 2019·ACS Biomaterials Science & Engineering·Behdad DelavariPegah Varamini

❮ Previous
Next ❯

Related Concepts

Related Feeds

Aminoglycosides

Aminoglycoside is a medicinal and bacteriologic category of traditional Gram-negative antibacterial medications that inhibit protein synthesis and contain as a portion of the molecule an amino-modified glycoside. Discover the latest research on aminoglycoside here.

Adrenocortical Carcinoma

Hepatocellular carcinoma is the most common type of primary liver cancer and frequently occurs in individuals with chronic liver diseases like cirrhosis. Here is the latest research.

Carcinoma, Hepatocellular

Hepatocellular Carcinoma is a malignant cancer in liver epithelial cells. Discover the latest research on Hepatocellular Carcinoma here.

Breast Invasive Carcinoma

Invasive breast cancers indicate a spread into breast tissues and lymph nodes. Here are the latest discoveries pertaining to breast invasive carcinomas.

Breast Invasive Carcinoma (Keystone)

Invasive breast cancers indicate a spread into breast tissues and lymph nodes. Here are the latest discoveries pertaining to breast invasive carcinomas.

Breast Tumorigenesis

Breast tumorigenesis involves the production or formation of tumor(s) in breast tissue. Discover the latest research on breast tumorigenesis here.

Aminoglycosides (ASM)

Aminoglycoside is a medicinal and bacteriologic category of traditional Gram-negative antibacterial medications that inhibit protein synthesis and contain as a portion of the molecule an amino-modified glycoside. Discover the latest research on aminoglycoside here.

Apoptosis in Cancer

Apoptosis is an important mechanism in cancer. By evading apoptosis, tumors can continue to grow without regulation and metastasize systemically. Many therapies are evaluating the use of pro-apoptotic activation to eliminate cancer growth. Here is the latest research on apoptosis in cancer.

Apoptosis

Apoptosis is a specific process that leads to programmed cell death through the activation of an evolutionary conserved intracellular pathway leading to pathognomic cellular changes distinct from cellular necrosis